Background/Rationale: To determine the suitability of published estimates of the US cost of Alzheimer’s disease (AD) for use in cost-effectiveness models for new AD treatments. Methods: A systematic literature review of published information on direct medical, direct nonmedical, indirect, and informal care costs for different levels of disease severity. Results: Nineteen studies were included in the review. In studies presenting mean costs by disease severity, the change in different types of costs with increasing disease severity varied, depending on the data sources and characteristics of patients with AD. In studies presenting the results of regression analyses, costs were shown to be independently associated with cognition, functional status, behavioral symptoms, and dependence. Conclusions: Published US studies (1) did not include all the types of costs and AD populations, and (2) generally did not include all the measures of disease severity that are needed for cost-effectiveness models.
A review of the methods used to estimate the cost of Alzheimer’s disease in the United States
Mauskopf, J., & Mucha, L. (2011). A review of the methods used to estimate the cost of Alzheimer’s disease in the United States. American Journal of Alzheimer's Disease and other Dementias, 26(4), 298-309. https://doi.org/10.1177/1533317511407481
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
The importance of quality data to track global progress in addressing stillbirths and neonatal mortality